Astellas Pharma Inc.
Astellas Pharma Inc. (ALPMF) Revenue
Annual & quarterly revenue history · segment & region breakdown
ALPMF · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAstellas Pharma Inc. trailing twelve-month (TTM) revenue is $2151B, an increase of 12.57% year-over-year from $2153B in FY2026.
Revenue trend
2026 – 2007 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2026-03-31 | $2153B | +$240.39B | +12.57% |
| 2025-03-31 | $1912B | +$308.65B | +19.25% |
| 2024-03-31 | $1604B | +$85.05B | +5.60% |
| 2023-03-31 | $1519B | +$222.46B | +17.16% |
| 2022-03-31 | $1296B | +$46.63B | +3.73% |
| 2021-03-31 | $1250B | -$51.31B | -3.94% |
| 2020-03-31 | $1301B | -$5.50B | -0.42% |
| 2019-03-31 | $1306B | +$6.03B | +0.46% |
| 2018-03-31 | $1300B | -$11.35B | -0.87% |
| 2017-03-31 | $1312B | -$61.04B | -4.45% |
Compare revenue vs peers
Drug Manufacturers - GeneralCompare ALPMF revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Astellas Pharma Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Astellas Pharma Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in JPY.
Data sourced from Astellas Pharma Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ALPMF revenue · 4 questionsALPMF's trailing twelve-month (TTM) revenue is $2151B. That is an increase of 12.57% year-over-year from $2153B in FY2026.
▸ Source: FMP · Astellas Pharma Inc. SEC filings · GAAP · Astellas Pharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026